NEW YORK, Nov. 21, 2022 /PRNewswire/ -- The Heparin Market share is expected to increase by USD 3009.44 million from 2022 to 2027, with an accelerated CAGR of 6.94% - according to the recent market study by Technavio. This report also offers a 5-year historic (2017-2021) data projection of market size, segment, and region. The Y-O-Y growth rate of the heparin market is estimated at 6.41% as of 2023. Moreover, the market is fragmented. Our analysts have conducted an internal and external analysis of vendors to help companies understand the wider business environment as well as the strength and weaknesses of key market players. Our report also forecasts the Bargaining Power of Buyers & Suppliers and the Threat of New Entrants & Rivalry ranging between LOW-HIGH during the forecast period.

Find Analysis of Price Sensitivity, Lifecycle, Customer Purchase Basket, Adoption Rates, and Purchase Criteria Prepared Exclusively by Technavio Research Analysts

  • One of the core components of customer landscape is Price Sensitivity – an analysis of which will help companies refine marketing strategies to gain a competitive advantage.   
  • Moreover, this report also provides impact of price sensitivity drivers (purchases are undifferentiated, purchase is a key cost to the buyer, and quality is not important) which are expected to range between LOW-HIGH from 2023-2027.
  • Our report provides extensive information on the customer landscape of the Heparin market, involving qualitative and quantitative intelligence. 

FOR A DETAILED OVERVIEW OF CUSTOMER LANDSCAPE, REQUEST SAMPLE PAGES

The Heparin Market Report Also Offers Information on the Criticality of Inputs, R&D, Capex, Technology, Labor, and Brand of 20 Vendors Listed Below –

  • Aspen Pharmacare Holdings
  • B. Braun SE
  • Baxter International Inc.
  • Dr. Reddys Laboratories Ltd.
  • Eisai Co. Ltd.
  • Fresenius SE & Co. KGaA
  • Hebei Changshan Biochemical
  • Hikma Pharmaceuticals Plc
  • Laboratorios Farmaceuticos Rovi
  • LEO Pharma AS
  • Nanjing Kingfriend Biochemical
  • Nichi Iko Pharmaceutical Co. Ltd.
  • Novartis AG
  • Opocrin SpA
  • Pfizer Inc.
  • Shenzhen Techdow Pharmaceutical
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.

DOWNLOAD A SAMPLE REPORT FOR MORE ACCESS

Chart & Data Table on 5-Year Historic (2017-2021) Market Size, Comparison and Y-O-Y Growth of Heparin Industry Segment

  • The market is segmented by Product (Low-molecular-weight Heparin and Others) and Route of Administration (Subcutaneous Injection and Intravenous/infusion).
  • By Product - The low-molecular-weight heparin segment shows a gradual increase in demand during 2023-2027.
  • Low-molecular-weight heparin inhibits the coagulation mechanism in the blood. It converts fibrinogen into fibrin through the activity of thrombin. It inhibits coagulation by activating antithrombin III.
  • The adoption of Low-molecular-weight heparin is expected to grow during the forecast period, owing to the wide availability and advantages of these products.

INTERESTED TO PROCURE THE DATA?

DOWNLOAD A SAMPLE REPORT

Increasing Prevalence of Blood Clotting Disorders is Notably Driving the Heparin Market Growth

The prevalence of various blood clotting disorders, such as hemophilia, Von Willebrand disease, hypercoagulable states, deep venous thrombosis, and clotting factor deficiencies, is rising significantly worldwide. According to the data published by the CDC in July 2020, approximately 400 babies in the US are born with hemophilia every year. As of February 2020, about 900,000 people in the US were affected by venous thromboembolism. The rising prevalence of various blood clotting diseases requires continuous monitoring for further medical interventions. This, in turn, is driving the growth of the market. Moreover, physicians recommend blood clotting or coagulation tests before major surgeries. These factors will further increase the demand for heparin during the forecast period.

TO ACCESS WHAT ARE THE LATEST DRIVERS, TRENDS, AND CHALLENGES INFLUENCING THE GROWTH OF THIS MARKET, REQUEST A SAMPLE REPORT

Chart & Data Table on Historic Market Size (2017-2021), Comparison and Y-O-Y Growth of 11 Countries of Heparin Industry

  • The market is segmented by Geography into North America (The U.S. and Canada), Europe (U.K., Germany, France, and Rest of Europe), Asia (China and India), and Rest of World (Argentina, Australia, and Brazil).
  • Europe is projected to contribute 39% of the market's growth by 2027. Europe was the most significant contributing region in the heparin market, primarily owing to the increasing prevalence of obesity and smoking and the high consumption of alcohol. The increasing number of surgeries is another factor driving the growth of the market in Europe. 
  • In 2020, the outbreak of COVID-19 in European countries led to a rise in the demand for heparin for treating patients with severe symptoms of COVID-19. This had a positive impact on the regional market. During the forecast period, the market in Europe will further be driven by factors such as the growing geriatric population, the rising number of product launches, growing healthcare spending, and the increasing prevalence of contagious diseases and various chronic conditions. 

FOR MORE INSIGHTS ON THE MARKET SHARE OF VARIOUS REGIONS, VIEW A PDF SAMPLE NOW!

Related Reports

Africa HIV Treatment Drugs Market by Drug Class, Route of Administration, and Geography - Forecast and Analysis - 2023-2027 – The market share is expected to increase by USD 321.6 million from 2022 to 2027, and the market's growth momentum will accelerate at a CAGR of 3.76%. Furthermore, this report extensively covers market segmentations by drug class (reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, and fusion inhibitors), route of administration (oral drugs and injectable drugs), and geography (North America, Europe, Asia, and Rest of World (ROW)).  To get more exclusive research insights: VIEW A SUMMARY OF THE REPORT FOR MORE 

Infectious Disease Market by Product, End-user, and Geography - Forecast and Analysis 2023-2027 – The market share is expected to increase by USD 104.81 billion from 2022 to 2027, and the market's growth momentum will accelerate at a CAGR of 12.49%. The increasing prevalence of infectious diseases is one of the key factors driving market growth. To get more exclusive research insights: VIEW A SUMMARY OF THE REPORT FOR MORE

Heparin Market Scope

Report Coverage

Details

Page number

120

Base year

2022

Historical year

2017-2021

Forecast period

2023-2027

Growth momentum & CAGR

Accelerate at a CAGR of 6.94%

Market growth 2023-2027

USD 3009.44 million

Market structure

Fragmented

YoY growth (%)

6.41

Regional analysis

Europe, North America, Asia, and the Rest of the World (ROW)

Performing market contribution

Europe at 39%

Key consumer countries

US, UK, Germany, France, and China

Competitive landscape

Leading companies, Competitive Strategies, Consumer engagement scope

Key companies profiled

Aspen Pharmacare Holdings, B. Braun SE, Baxter International Inc., Dr. Reddys Laboratories Ltd., Eisai Co. Ltd., Fresenius SE & Co. KGaA, Hebei Changshan Biochemical, Hikma Pharmaceuticals Plc, Laboratorios Farmaceuticos Rovi, LEO Pharma AS, Nanjing Kingfriend Biochemical, Nichi Iko Pharmaceutical Co. Ltd., Novartis AG, Opocrin SpA, Pfizer Inc., Sanofi SA, Shanghai Fosun Pharmaceutical Group Co. Ltd., Shenzhen Techdow Pharmaceutical, Teva Pharmaceutical Industries Ltd., and Viatris Inc.

Market dynamics

Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period.

Customization purview

If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Browse Health Care Market Reports

Table of Contents

1 Executive Summary

  • 1.1 Market overview 
    • Exhibit 01: Executive Summary – Chart on Market Overview
    • Exhibit 02: Executive Summary – Data Table on Market Overview
    • Exhibit 03: Executive Summary – Chart on Global Market Characteristics
    • Exhibit 04: Executive Summary – Chart on Market by Geography
    • Exhibit 05: Executive Summary – Chart on Market Segmentation by Product
    • Exhibit 06: Executive Summary – Chart on Market Segmentation by Route of Administration
    • Exhibit 07: Executive Summary – Chart on Incremental Growth
    • Exhibit 08: Executive Summary – Data Table on Incremental Growth
    • Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

  • 2.1 Market ecosystem 
    • Exhibit 10: Parent market
    • Exhibit 11: Market Characteristics

3 Market Sizing

  • 3.1 Market definition 
    • Exhibit 12: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis 
    • Exhibit 13: Market segments
  • 3.3 Market size 2022
  • 3.4 Market outlook: Forecast for 2022-2027 
    • Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
    • Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
    • Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
    • Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

  • 4.1 Global heparin market 2017 - 2021 
    • Exhibit 18: Historic Market Size – Data Table on Global heparin market 2017 - 2021 ($ million)
  • 4.2 Product Segment Analysis 2017 - 2021 
    • Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)
  • 4.3 Route of administration Segment Analysis 2017 - 2021
    • Exhibit 20: Historic Market Size – Route of administration Segment 2017 - 2021 ($ million)
  • 4.4 Geography Segment Analysis 2017 - 2021 
    • Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)
  • 4.5 Country Segment Analysis 2017 - 2021 
    • Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

  • 5.1 Five forces summary 
    • Exhibit 23: Five forces analysis - Comparison between2022 and 2027
  • 5.2 Bargaining power of buyers 
    • Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
  • 5.3 Bargaining power of suppliers 
    • Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
  • 5.4 Threat of new entrants 
    • Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
  • 5.5 Threat of substitutes 
    • Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
  • 5.6 Threat of rivalry 
    • Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
  • 5.7 Market condition 
    • Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product

  • 6.1 Market segments 
    • Exhibit 30: Chart on Product - Market share 2022-2027 (%)
    • Exhibit 31: Data Table on Product - Market share 2022-2027 (%)
  • 6.2 Comparison by Product 
    • Exhibit 32: Chart on Comparison by Product
    • Exhibit 33: Data Table on Comparison by Product
  • 6.3 Low-molecular-weight heparin - Market size and forecast 2022-2027 
    • Exhibit 34: Chart on Low-molecular-weight heparin - Market size and forecast 2022-2027 ($ million)
    • Exhibit 35: Data Table on Low-molecular-weight heparin - Market size and forecast 2022-2027 ($ million)
    • Exhibit 36: Chart on Low-molecular-weight heparin - Year-over-year growth 2022-2027 (%)
    • Exhibit 37: Data Table on Low-molecular-weight heparin - Year-over-year growth 2022-2027 (%)
  • 6.4 Others - Market size and forecast 2022-2027
    • Exhibit 38: Chart on Others - Market size and forecast 2022-2027 ($ million)
    • Exhibit 39: Data Table on Others - Market size and forecast 2022-2027 ($ million)
    • Exhibit 40: Chart on Others - Year-over-year growth 2022-2027 (%)
    • Exhibit 41: Data Table on Others - Year-over-year growth 2022-2027 (%)
  • 6.5 Market opportunity by Product 
    • Exhibit 42: Market opportunity by Product ($ million)

7 Market Segmentation by Route of Administration

  • 7.1 Market segments 
    • Exhibit 43: Chart on Route of Administration - Market share 2022-2027 (%)
    • Exhibit 44: Data Table on Route of Administration - Market share 2022-2027 (%)
  • 7.2 Comparison by Route of Administration 
    • Exhibit 45: Chart on Comparison by Route of Administration
    • Exhibit 46: Data Table on Comparison by Route of Administration
  • 7.3 Subcutaneous injection - Market size and forecast 2022-2027 
    • Exhibit 47: Chart on Subcutaneous injection - Market size and forecast 2022-2027 ($ million)
    • Exhibit 48: Data Table on Subcutaneous injection - Market size and forecast 2022-2027 ($ million)
    • Exhibit 49: Chart on Subcutaneous injection - Year-over-year growth 2022-2027 (%)
    • Exhibit 50: Data Table on Subcutaneous injection - Year-over-year growth 2022-2027 (%)
  • 7.4 Intravenous/infusion - Market size and forecast 2022-2027
    • Exhibit 51: Chart on Intravenous/infusion - Market size and forecast 2022-2027 ($ million)
    • Exhibit 52: Data Table on Intravenous/infusion - Market size and forecast 2022-2027 ($ million)
    • Exhibit 53: Chart on Intravenous/infusion - Year-over-year growth 2022-2027 (%)
    • Exhibit 54: Data Table on Intravenous/infusion - Year-over-year growth 2022-2027 (%)
  • 7.5 Market opportunity by Route of Administration
    • Exhibit 55: Market opportunity by Route of Administration ($ million)

8 Customer Landscape

  • 8.1 Customer landscape overview 
    • Exhibit 56: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

  • 9.1 Geographic segmentation 
    • Exhibit 57: Chart on Market share by geography 2022-2027 (%)
    • Exhibit 58: Data Table on Market share by geography 2022-2027 (%)
  • 9.2 Geographic comparison 
    • Exhibit 59: Chart on Geographic comparison
    • Exhibit 60: Data Table on Geographic comparison
  • 9.3 Europe - Market size and forecast 2022-2027
    • Exhibit 61: Chart on Europe - Market size and forecast 2022-2027 ($ million)
    • Exhibit 62: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
    • Exhibit 63: Chart on Europe - Year-over-year growth 2022-2027 (%)
    • Exhibit 64: Data Table on Europe - Year-over-year growth 2022-2027 (%)
  • 9.4 North America - Market size and forecast 2022-2027
    • Exhibit 65: Chart on North America - Market size and forecast 2022-2027 ($ million)
    • Exhibit 66: Data Table on North America - Market size and forecast 2022-2027 ($ million)
    • Exhibit 67: Chart on North America - Year-over-year growth 2022-2027 (%)
    • Exhibit 68: Data Table on North America - Year-over-year growth 2022-2027 (%)
  • 9.5 Asia - Market size and forecast 2022-2027
    • Exhibit 69: Chart on Asia - Market size and forecast 2022-2027 ($ million)
    • Exhibit 70: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
    • Exhibit 71: Chart on Asia - Year-over-year growth 2022-2027 (%)
    • Exhibit 72: Data Table on Asia - Year-over-year growth 2022-2027 (%)
  • 9.6 Rest of World (ROW) - Market size and forecast 2022-2027
    • Exhibit 73: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
    • Exhibit 74: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
    • Exhibit 75: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
    • Exhibit 76: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
  • 9.7 US - Market size and forecast 2022-2027
    • Exhibit 77: Chart on US - Market size and forecast 2022-2027 ($ million)
    • Exhibit 78: Data Table on US - Market size and forecast 2022-2027 ($ million)
    • Exhibit 79: Chart on US - Year-over-year growth 2022-2027 (%)
    • Exhibit 80: Data Table on US - Year-over-year growth 2022-2027 (%)
  • 9.8 UK - Market size and forecast 2022-2027
    • Exhibit 81: Chart on UK - Market size and forecast 2022-2027 ($ million)
    • Exhibit 82: Data Table on UK - Market size and forecast 2022-2027 ($ million)
    • Exhibit 83: Chart on UK - Year-over-year growth 2022-2027 (%)
    • Exhibit 84: Data Table on UK - Year-over-year growth 2022-2027 (%)
  • 9.9 Germany - Market size and forecast 2022-2027
    • Exhibit 85: Chart on Germany - Market size and forecast 2022-2027 ($ million)
    • Exhibit 86: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
    • Exhibit 87: Chart on Germany - Year-over-year growth 2022-2027 (%)
    • Exhibit 88: Data Table on Germany - Year-over-year growth 2022-2027 (%)
  • 9.10 China - Market size and forecast 2022-2027
    • Exhibit 89: Chart on China - Market size and forecast 2022-2027 ($ million)
    • Exhibit 90: Data Table on China - Market size and forecast 2022-2027 ($ million)
    • Exhibit 91: Chart on China - Year-over-year growth 2022-2027 (%)
    • Exhibit 92: Data Table on China - Year-over-year growth 2022-2027 (%)
  • 9.11 France - Market size and forecast 2022-2027
    • Exhibit 93: Chart on France - Market size and forecast 2022-2027 ($ million)
    • Exhibit 94: Data Table on France - Market size and forecast 2022-2027 ($ million)
    • Exhibit 95: Chart on France - Year-over-year growth 2022-2027 (%)
    • Exhibit 96: Data Table on France - Year-over-year growth 2022-2027 (%)
  • 9.12 Market opportunity by geography 
    • Exhibit 97: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

  • 10.1 Market drivers
  • 10.2 Market challenges
  • 10.3 Impact of drivers and challenges 
    • Exhibit 98: Impact of drivers and challenges in 2022 and 2027
  • 10.4 Market trends

11 Vendor Landscape

  • 11.1 Overview
  • 11.2 Vendor landscape 
    • Exhibit 99: Overview on Criticality of inputs and Factors of differentiation
  • 11.3 Landscape disruption 
    • Exhibit 100: Overview on factors of disruption
  • 11.4 Industry risks 
    • Exhibit 101: Impact of key risks on business

12 Vendor Analysis

  • 12.1 Vendors covered 
    • Exhibit 102: Vendors covered
  • 12.2 Market positioning of vendors 
    • Exhibit 103: Matrix on vendor position and classification
  • 12.3 Aspen Pharmacare Holdings 
    • Exhibit 104: Aspen Pharmacare Holdings - Overview
    • Exhibit 105: Aspen Pharmacare Holdings - Business segments
    • Exhibit 106: Aspen Pharmacare Holdings - Key offerings
    • Exhibit 107: Aspen Pharmacare Holdings - Segment focus
  • 12.4 B. Braun SE 
    • Exhibit 108: B. Braun SE - Overview
    • Exhibit 109: B. Braun SE - Business segments
    • Exhibit 110: B. Braun SE - Key news
    • Exhibit 111: B. Braun SE - Key offerings
    • Exhibit 112: B. Braun SE - Segment focus
  • 12.5 Baxter International Inc. 
    • Exhibit 113: Baxter International Inc. - Overview
    • Exhibit 114: Baxter International Inc. - Business segments
    • Exhibit 115: Baxter International Inc. - Key news
    • Exhibit 116: Baxter International Inc. - Key offerings
    • Exhibit 117: Baxter International Inc. - Segment focus
  • 12.6 Eisai Co. Ltd. 
    • Exhibit 118: Eisai Co. Ltd. - Overview
    • Exhibit 119: Eisai Co. Ltd. - Business segments
    • Exhibit 120: Eisai Co. Ltd. - Key offerings
    • Exhibit 121: Eisai Co. Ltd. - Segment focus
  • 12.7 Fresenius SE and Co. KGaA 
    • Exhibit 122: Fresenius SE and Co. KGaA - Overview
    • Exhibit 123: Fresenius SE and Co. KGaA - Business segments
    • Exhibit 124: Fresenius SE and Co. KGaA - Key news
    • Exhibit 125: Fresenius SE and Co. KGaA - Key offerings
    • Exhibit 126: Fresenius SE and Co. KGaA - Segment focus
  • 12.8 Hikma Pharmaceuticals Plc 
    • Exhibit 127: Hikma Pharmaceuticals Plc - Overview
    • Exhibit 128: Hikma Pharmaceuticals Plc - Business segments
    • Exhibit 129: Hikma Pharmaceuticals Plc - Key offerings
    • Exhibit 130: Hikma Pharmaceuticals Plc - Segment focus
  • 12.9 Laboratorios Farmaceuticos Rovi 
    • Exhibit 131: Laboratorios Farmaceuticos Rovi - Overview
    • Exhibit 132: Laboratorios Farmaceuticos Rovi - Business segments
    • Exhibit 133: Laboratorios Farmaceuticos Rovi - Key offerings
    • Exhibit 134: Laboratorios Farmaceuticos Rovi - Segment focus
  • 12.10 Nanjing Kingfriend Biochemical 
    • Exhibit 135: Nanjing Kingfriend Biochemical - Overview
    • Exhibit 136: Nanjing Kingfriend Biochemical - Product / Service
    • Exhibit 137: Nanjing Kingfriend Biochemical - Key offerings
  • 12.11 Nichi Iko Pharmaceutical Co. Ltd. 
    • Exhibit 138: Nichi Iko Pharmaceutical Co. Ltd. - Overview
    • Exhibit 139: Nichi Iko Pharmaceutical Co. Ltd. - Product / Service
    • Exhibit 140: Nichi Iko Pharmaceutical Co. Ltd. - Key offerings
  • 12.12 Novartis AG 
    • Exhibit 141: Novartis AG - Overview
    • Exhibit 142: Novartis AG - Business segments
    • Exhibit 143: Novartis AG - Key offerings
    • Exhibit 144: Novartis AG - Segment focus
  • 12.13 Pfizer Inc. 
    • Exhibit 145: Pfizer Inc. - Overview
    • Exhibit 146: Pfizer Inc. - Product / Service
    • Exhibit 147: Pfizer Inc. - Key news
    • Exhibit 148: Pfizer Inc. - Key offerings
  • 12.14 Sanofi SA 
    • Exhibit 149: Sanofi SA - Overview
    • Exhibit 150: Sanofi SA - Business segments
    • Exhibit 151: Sanofi SA - Key news
    • Exhibit 152: Sanofi SA - Key offerings
    • Exhibit 153: Sanofi SA - Segment focus
  • 12.15 Shenzhen Techdow Pharmaceutical 
    • Exhibit 154: Shenzhen Techdow Pharmaceutical - Overview
    • Exhibit 155: Shenzhen Techdow Pharmaceutical - Product / Service
    • Exhibit 156: Shenzhen Techdow Pharmaceutical - Key offerings
  • 12.16 Teva Pharmaceutical Industries Ltd. 
    • Exhibit 157: Teva Pharmaceutical Industries Ltd. - Overview
    • Exhibit 158: Teva Pharmaceutical Industries Ltd. - Business segments
    • Exhibit 159: Teva Pharmaceutical Industries Ltd. - Key news
    • Exhibit 160: Teva Pharmaceutical Industries Ltd. - Key offerings
    • Exhibit 161: Teva Pharmaceutical Industries Ltd. - Segment focus
  • 12.17 Viatris Inc. 
    • Exhibit 162: Viatris Inc. - Overview
    • Exhibit 163: Viatris Inc. - Business segments
    • Exhibit 164: Viatris Inc. - Key offerings
    • Exhibit 165: Viatris Inc. - Segment focus

13 Appendix

  • 13.1 Scope of the report
  • 13.2 Inclusions and exclusions checklist 
    • Exhibit 166: Inclusions checklist
    • Exhibit 167: Exclusions checklist
  • 13.3 Currency conversion rates for US$ 
    • Exhibit 168: Currency conversion rates for US$
  • 13.4 Research methodology 
    • Exhibit 169: Research methodology
    • Exhibit 170: Validation techniques employed for market sizing
    • Exhibit 171: Information sources
  • 13.5 List of abbreviations 
    • Exhibit 172: List of abbreviations

About Us

 

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research

Jesse Maida

Media & Marketing Executive

US: +1 844 364 1100

UK: +44 203 893 3200

Email: media@technavio.com

Website: www.technavio.com/

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/heparin-market-2023-2027-along-with-5-year-historic-2017-2021-industry-size--comparison-of-20-vendors-and-11-countries-301682464.html

SOURCE Technavio

Originally published on the TownNews Content Exchange.